Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) EBITDA Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of EBITDA Margin data on record, last reported at 238.71% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 41688.0% year-over-year to 238.71%; the TTM value through Dec 2025 reached 98.22%, up 12789.0%, while the annual FY2025 figure was 98.22%, 12789.0% up from the prior year.
  • EBITDA Margin reached 238.71% in Q4 2025 per LCTX's latest filing, up from 102.85% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 238.71% in Q4 2025 and bottomed at 1803.07% in Q1 2021.
  • Average EBITDA Margin over 5 years is 404.11%, with a median of 301.45% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: skyrocketed 168094bps in 2022, then plummeted -36297bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 301.45% in 2021, then fell by -15bps to 346.68% in 2022, then grew by 10bps to 311.1% in 2023, then skyrocketed by 43bps to 178.17% in 2024, then skyrocketed by 234bps to 238.71% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 238.71% in Q4 2025, 102.85% in Q3 2025, and 715.37% in Q2 2025.